Drug intelligence / Profile preview

TetraVax-DV

Development stage: Phase 3
Lead developer: National Institutes of Health
Modality: Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

TetraVax-DV is a lyophilized, tetravalent, live-attenuated chimeric vaccine developed to prevent dengue disease. It contains attenuated strains of all four dengue virus serotypes and is designed to induce immunity against each. The vaccine was originally formulated by the US National Institutes of Health (NIH) and has been licensed for production in several countries including Brazil (Butantan Institute), India (Biological E/Panacea Biotec), and Vietnam (Vabiotech). Merck & Co has also in-licensed the vaccine for further development. The mechanism of action involves immunostimulation—eliciting both humoral and cellular immune responses that mimic natural infection but without causing disease. Phase I studies have shown high rates of tetravalent seroconversion after a single dose with both TV003 and TV005 formulations[4][5]. The vaccine is being evaluated for use in endemic regions as well as among travelers or military personnel.

Brand names: TetraVax-DV
Other names: Butantan-Dengue VaccineButantan-DV

Targets

TLR3 (Toll-like receptor 3)

Beyond the preview

Go deeper on TetraVax-DV.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TetraVax-DV.

Explore the full profile